Raasch Walter, Bartels Torsten, Schwartz Christopher, Häuser Walter, Rütten Hartmut, Dominiak Peter
Institute of Experimental and Clinical Pharmacology and Toxicology, Medical University of Lübeck, Germany.
J Hypertens. 2002 Dec;20(12):2495-504. doi: 10.1097/01.hjh.0000042885.24999.e9.
It is well established that angiotensin-converting enzyme (ACE) inhibitors (ACEI) reduce blood pressure (BP) and hypertrophy of the left ventricle and vessels. The aim of our study was to compare chemically different ACEIs regarding their ability to modulate left ventricular and media hypertrophy, ACE activity and plasma endothelin-1 concentrations in spontaneously hypertensive rats (SHRs).
After establishing equi-effective dose regimes, SHRs were treated (3 months) with captopril, enalapril, fosinopril or ramipril (2 x 25, 10, 20 or 1 mg/kg per day or corresponding 1% doses for studying blood pressure-independent effects).
Systolic blood pressure was reduced in SHRs receiving high doses of captopril, enalapril, fosinopril or ramipril (-61, -54, -35 and -47 mmHg), whereas low doses were ineffective. Left ventricular weight was decreased in animals treated with high doses (captopril/enalapril/fosinopril/ramipril: -17/-19/-17/-19%), but not low doses of agents. Media thickness of thoracal aorta was reduced by administering high doses (captopril/enalapril/fosinopril/ramipril: -31/-32/-27/-26%) and low doses (-16/-22/-22/-19%) of agents. ACE activity was reduced in heart, aorta and kidney of rats treated with high and low doses of all ACE inhibitors, whereby high doses showed more pronounced effects. Plasma endothelin-1 concentrations were not altered. A blood-pressure-ineffective treatment with an AT -antagonist revealed similar effects on cardiovascular hypertrophy.
ACEIs reduce cardiovascular hypertrophy uniformly via an AT -receptor- mediated mechanism, reinforcing the opinion that ACEI effects are indeed class effects. The significance of local renin-angiotensin systems was confirmed by antihypertrophic effects in the aorta that were apparent in the absence of any blood pressure reduction.
血管紧张素转换酶(ACE)抑制剂(ACEI)可降低血压(BP)并减轻左心室和血管的肥厚,这一点已得到充分证实。我们研究的目的是比较化学结构不同的ACEI对自发性高血压大鼠(SHR)左心室和血管中层肥厚、ACE活性及血浆内皮素-1浓度的调节能力。
在确定等效剂量方案后,用卡托普利、依那普利、福辛普利或雷米普利对SHR进行治疗(3个月)(每天2×25、10、20或1mg/kg或相应的1%剂量用于研究与血压无关的效应)。
接受高剂量卡托普利、依那普利、福辛普利或雷米普利的SHR收缩压降低(分别为-61、-54、-35和-47mmHg),而低剂量无效。高剂量药物治疗的动物左心室重量降低(卡托普利/依那普利/福辛普利/雷米普利:-17/-19/-17/-19%),但低剂量药物无效。高剂量(卡托普利/依那普利/福辛普利/雷米普利:-31/-32/-27/-26%)和低剂量(-16/-22/-22/-19%)药物均可使胸主动脉中层厚度降低。所有ACE抑制剂高剂量和低剂量治疗的大鼠心脏、主动脉和肾脏中ACE活性均降低,高剂量的作用更明显。血浆内皮素-1浓度未改变。用AT拮抗剂进行的无降压作用的治疗对心血管肥厚有类似影响。
ACEI通过AT受体介导的机制一致地减轻心血管肥厚,强化了ACEI的作用确实是类效应的观点。在无任何血压降低的情况下主动脉出现的抗肥厚效应证实了局部肾素-血管紧张素系统的重要性。